Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

Anti-infectivesPRM 5177
Dosage formSyrup
Oral

Abacavir 20 mg / ml

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2576
Dosage formTablets
Oral

Abacavir 300 mg, Lamivudine 150 mg, Zidovudine 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2577
Dosage formTablets
Oral

Abacavir 60 mg, Lamivudine 30 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2578
Dosage formTablets
Oral

Abacavir 600 mg, Atazanavir 300 mg, Lamivudine 300 mg, Ritonavir 100 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
HIV protease inhibitor + Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2579
Dosage formTablets
Oral

Abacavir 600 mg, Dolutegravir 50 mg, Lamivudine 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
HIV integrase inhibitor + Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2580
Dosage formTablets
Oral

Abacavir 600 mg, Lamivudine 300 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2581
Dosage formTablets
Oral

Abacavir Sulfate 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2582
Dosage formTablets
Oral

Abacavir Sulphate 120 mg, Lamivudine 60 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Nucleoside/nucleotide reverse-transcriptase inhibitor
Manufacturing stream
Non-beta-lactam
BCS class
Class III
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2617
Dosage formTablets
Oral

Acyclovir 1200 mg (SR)

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 0072
Dosage formTablets
Oral

Acyclovir 200 mg Film Coated

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 644
Anti-infectivesPRM 0073
Dosage formTablets
Oral

Acyclovir 200 mg Uncoated

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 644
Anti-infectivesPRM 1973
Dosage formDry-powder injectables
Parenteral

Acyclovir 250 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 0074
Dosage formTablets
Oral

Acyclovir 400 mg Uncoated

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 0075
Dosage formTablets
Oral

Acyclovir 400 mg Uncoated Dispersible

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1974
Dosage formDry-powder injectables
Parenteral

Acyclovir 500 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 0076
Dosage formTablets
Oral

Acyclovir 800 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
Class IV
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2626
Dosage formTablets
Oral

Aeterolane Malate 150 mg, Piperaquine Phosphate 750 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Antimalarial
Manufacturing stream
Non-beta-lactam
BCS class
Not specified
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 5434
Dosage formOral suspension
Oral

Albendazole 2.5% w/v

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2633
Dosage formTablets
Oral

Albendazole 200 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
Class II
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1667
Dosage formOral suspension
Oral

Albendazole 200 mg / 5 ml

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 317
Anti-infectivesPRM 1455
Dosage formSyrup
Oral

Albendazole 200 mg, Ivermectin 1.5 mg / 5 ml

Route
Oral
Formulation type
Oral liquid syrup
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 5435
Dosage formOral suspension
Oral

Albendazole 200 mg, Ivermectin 3 mg / 5 ml

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 0078
Dosage formTablets
Oral

Albendazole 200 mg, Levamisole 50 mg

Route
Oral
Formulation type
Solid oral tablet
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
Class II (mixed)
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 5436
Dosage formOral suspension
Oral

Albendazole 200 mg, Levamisole 50 mg / 5 ml

Route
Oral
Formulation type
Oral liquid suspension
Pharmacological class
Anthelmintic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Oral Liquid
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product